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HOW TO READ 
"SCIENCE vs. AIDS" 
This publication is produced to be read in ·two different 
ways. On the righ! side of the pamphlet are the highlights of 
the Seven Springs conference proceedings written 'in non­
technical language. On the left side are easy-to-understand 
summaries of several key scientific issues · pertaining to the 
AIDS epidemic. This background is intended to provide 
readers with the basic information necessary to help them 
comprehend the complex task facing scientists as they work to 
understand the AIDS virus and develop treatments against it. 





n the spring of 1988, my laboratory colleague Professor
Ralph Steinman and I were hosts to a small group of fellow 
scientists at a meeting at Seven Springs, The Rockefeller 
Universitys conference center in Westchester, New York, a 
quiet enclave some forty-five minutes north of the University's 
Manhattan campus. 
The thirty-one participants, representing a number of dif­
ferent disciplines and institutions, had in common that each 
is a leader in research that bears directly or potentially on the 
problem of AIDS. Our object was to spend a couple of days 
together, free from the intrusions of the laboratory, the clinic, 
and the press, sharing our ideas and the perspectives derived 
from our individual investigations in an attempt to assess 
where we are in understanding this terrible disease, and 
where our future efforts should be directed. 
While the meeting was being planned, it was suggested to 
us that a report of our discussions would be of interest· to 
many people outside the research community. We invited 
science writer Lois Wingerson to att�nd the meeting and 
prepare this publication. (A scientific summary of the meeting 
by Dr. Steinman and myself appeared in the December 1988 
issue of the Journal of Experimental Medicine.) 
We would like to express our appreciation to Rockefeller 
University Council member Katherine Morgan Deane, and to 
Rockefeller University trustee Disque Deane for their gener­
ous support of the Seven Springs project. 
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Lymphocytes as seen with 
a scanning electron micro­
scope, which magnifies 
actual sizes 1,600 times, 
and provides a high reso­
lution view of the contours 
of the lymphocyte surface. 
However, microscopy does 
not reveal the chemical and 
functional differences that 
exist among lymphocytes. 
About half the lympho­
cytes in human blood 
carry a surface molecule 
called T4 or CD4. CD4-
bearing lymphocytes make 
molecules called lympho� 
kines (or interleukins) 
which help generate im­
munity. It is the malfunc­
tion and loss of CD4 
helper cel ls that is so seri­
ous in AIDS. 




hat we already know about the acquired immune defi­
ciency syndrome fills thousands of pages in scientific 
journals, but it is not nearly enough. There is no cure in sight, 
and the epidemic continues to spread. 
AIDS is still eluding scientists because it is an entirely new 
challenge-caused by a kind of virus new to medical science, 
infecting a complex network of human cells that is still poorly 
understood. Meeting this challenge demands a diverse mix­
ture of scientific specialists, people who have had little reason 
to pool their expertise in the past. Now there is a most urgent 
reason, and in May 1988, there was an opportunity. 
For two days, a small group of top AIDS researchers met in 
seclusion at a conference center in Mount Kisco, New York. It 
was an event unique in the history of AIDS research. There 
were no press reports, no audience, no formal presentations, 
no strict agenda; just thirty-two scientists and a slide projector 
in the small library of an old estate. Their deliberations remain 
as pertinent now as they were at the time of the conference. 
The sponsors from The Rockefeller University had invited 
the participants to the Seven Springs Conference Center to 
address a few basic questions: What do we know about AIDS, 
and what do we still need to learn? Which questions can be 
answered, and how? Which questions cannot be answered at 
all? 
The decisions came from different vantage points. A few 
participants were medical researchers who encounter AIDS 
patients daily. Others had rarely if ever seen an AIDS patient, 
but spend their days studying cells in laboratory dishes. Some 
set their focus even deeper, on the molecules inside viruses 
and cells. 
The retrovirologists at the conference had spent years in an 
esoteric endeavor, studying a class of viruses not known be­
fore 1980 to infect human beings. When the AIDS virus joined 
the class, the work of these scientists was suddenly pivotal. A 
few people in attendance had not studied AIDS at all, but had 
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Dr. Robert North 
Dr. Bernard Fields 
(left to right) 
Dr. Jay A .  Levy and 
Dr. Malcolm A. Martin 
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Lerner and Dr. Hilary 
Koprowski (below right) 
Dr. Anthony Fauci, 
Dr. David K latzman and 
Dr. Samuel Broder 
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focused on the normal immune system which counteracts 
diseases inside the human body-and which the AIDS virus 
invades and destroys. 
Exactly a month after the Seven Springs meeting, the chair­
man of a much larger gathering-an international AIDS con­
ference in Stockholm-would tell his audience of 7,000 that 
the news about AIDS was "even more frightening than we 
have expected." Indeed, the press reports were grim: 
On average, it takes about eight years after initial infection 
to develop the first signs of AIDS. Eight years after the first 
reported cases, therefore, the full impact of the disease was 
just beginning to be evident. It might be even worse than it 
appeared: In some individuals, according to a new kind of 
test, the virus seemed to hide out inside cells without even 
causing an immune response that can be recognized in a 
blood test. Once infected, a person's odds of survival-speak­
ing very optimistically-may be one percent. 
The scientists meeting at Seven Springs knew all this � 
month earlier, but their consensus for the future seemed less 
grim than the press reports that would come from Stockholm. 
Much does remain to be done before the AIDS crisis is 
solved. That fact has a mirror image, reflected at the Seven 
Springs conference: Much can be done. 
AIDS 
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t is tantalizing, but probably futile, to ask how AIDS began.
The AIDS virus shows similarities to some viruses prevalent 
in African monkeys, and one theory holds that it spread to a 
human being from a monkey, perhaps as recently as the 
second half of this century. But evolutionary studies from 
Japan suggest that the difference between the AIDS virus and 
its simian relatives dates back much farther, perhaps thou­
sands of years. Then why did it gain a·foothold as a disease 
probably no earlier than 1960 (to judge from studies of stored 
blood)? 
We may never know. The same question can be asked about 
the microorganisms that cause bubonic plague, or polio, or 
rheumatic fever, or the agents that may cause arthritis or 
multiple sclerosis. And again there is no good explanation as 
to how these diseases arose, where and why, and why they 
may wane. The human population has a most unstable truce 
with viruses, which are in their own ways as inscrutable and 
changeable as we are. 
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THE SEVEN SPRINGS 
INTERNATIONAL 
CONFERENCE ON THE 
IMMUNOLOGICAL AND 
INFECTIOUS SEQUELAE 
OF AIDS:· A SUMMARY 
T
he adversary is incapable of designing strategies. It does
not understand malevolence. But for everyone who thinks 
about the AIDS virus-including the scientists who know it 
best, gathered at Seven Springs-it is almost irresistible to 
regard the virus as a deliberately crafty and insidious enemy. 
Its name describes its methods: human immunodeficiency 
virus, or HIV Actually, there are two forms of the AIDS virus, 
HIVl and HIV2, which have some structural differences but 
similar disastrous effects. At the outset, the conversation at 
Seven Springs centered on viral guerilla tactics: the ways in 
which HIV commandeers and disarms the very immune cells 
that ought to discover and destroy it. 
In one sense, scientists already know HIV inside and out. 
Inside, a core of proteins and molecules of genetic material, 
RNA. Outside, a coat of glycoprotein, protein wrapped in 
sugar. (See page 42.) Researchers have no trouble recognizing 
HIV in the laboratory, using molecular ID tags called antibod­
ies, which an animal's immune system will manufacture in 
response to HIV's presence in its blood. 
In another sense, scientists know almost nothing about 
HIV The details of its life history and ordinary affairs remain 
a mystery. It is as if the FBI had identified a terrorist group and 
possessed photographs, fingerprints, and a good descrip­
tion-but had no idea whatever of its whereabouts or 
movements. 
HIV gives medical science its first good opportunity to 
study the interaction of human beings and a class of viruses 
previously known only to infect animals, the lentiviruses. It's 
a field of study with many scholars, but a history of only five 
years. 
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BRIEF HISTORY 
OF AN EPIDEMIC 
At the outset, what we would come to call AIDS was 
J-\.merely a disturbiilg, somewhat intriguing, little puzzle. 
A few otherwise healthy young American men began to suc­
cumb to rare infections they had no business catching: Pneu­
mocystis carinii, Mycobacterium avium tyberculosis, diseases 
of the Third World or, in the United States, of the old and 
debilitated. 
In June 1981, 152 such cases were reported in a medical 
journal. Nine of ten victims were homosexual or bisexual 
young men .. Fortunately, the first suggested name-GRID, 
for gay-related immune deficiency-did noMake root. After 
1981, the number of cases would double every six months and 
reach far beyond the homosexual community. 
Another name gained acceptance: acquired immune defi� 
ciency syndrome, or AIDS. The syndrome "Yas defined as: 
• progressive immune deficiency;
• disseminated infections such as herpes, candidiasis, Pneu­
mocystis pneumonia;
• perhaps Kaposi's sarcoma, a tumor of tissues lining blood
vessels and organs, formerly known mostly among older
Italian or Jewish men, or Africans.
1981: The cause of the disease was a matter of speculation. 
Under consideration were autoimmunity, damage from 
sperm in anal intercourse, recreational drugs favored by 
homosexuals or, most likely, a new virus. In general, 
most governments and the press treated AIDS as a 
curiosity. 
1982: Cases had now been reportea from Haiti, Europe, and 
Africa. An outbreak of Kaposi's sarcoma erupted in Zam­
bia. The diarrhea, fever, and weight loss common among 
AIDS patients were · so prevalent in parts of Africa for 
other reasons that AIDS was initially very difficult to 
pinpoint on that continent. 
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A FREE AGENT? 
At its start, the Seven Springs conference grappled with 
.fl.one of the most troublesome unknowns about HIV: 
whether the virus tends to infect cells while it floats freely in 
the blood, or whether it always spreads-with one excep­
tion-from cell to cell. 
The exception is hemophilia, the inherited bleeding disor­
der in which blood fails to clot properly. People with hemophi­
lia can contract HIV infections if the virus contaminates 
preparations of Factor VIII, which they must take to stop 
bleeding. This blood fraction, prepared from the concentrated 
plasma of many donors, is filtered finely enough to extract 
bacteria and whole cells, but not free viruses. The HIV in 
Factor VIII must be transmitted as a free agent-but was the 
virus freed by the plasma preparation, or was it free in the 
donor's plasma in the first place? 
Moreover, is such cell-free passage of the virus really an 
exception? The answer is elusive, because the free virus is 
elusive. People who are infected but not yet ill are likely to 
transmit the virus to others, yet it is rare in their body fluids. 
The only body fluid where HIV is abundant in cell-free form 
is the cerebrospinal fluid that bathes the spinal cord and the 
brain-hardly a major route for passage of HIV from one 
person to another. 
Precisely what, then, is the origin of the infection in the 
semen passed in sexual intercourse, or in the contaminated 
hypodermic needle which spreads HIV to an intravenous drug 
abuser? It's hardly an esoteric question, because a critical one 
follows: To control the spread of AIDS, must we prevent pas­
sage of free virus, infected cells, or both? And which cells? 
"The definitive experiment has yet to be done," said Mal­
colm Martin of the National Institute of Allergy and Infectious 
Diseases (NIAID). "Every meeting I go to we ask the same 
question. No one has the answer." 
Finding it will be difficult. Most AIDS patients have been 
infected for years before they develop symptoms. Ethically 
and practically, it's impossible to study the moment of infec­
tion, whether it is during intercourse or a needle prick. 
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1983: Intravenous drug abusers, people who have received 
blood transfusions since 1978, and people with hemo­
philia who take injections of the blood fraction Factor Vill, 
were added to the high-risk groups. 
During the same year, Luc Montagniers team at the 
Pasteur Institute identified a new virus from several 
patients with AIDS or with symptoms that precede 
the disease. 
1984: · Robert Gallo and coworkers at the National Institutes of 
Health also identified an AIDS virus (subsequently found 
to be very similar to MontaITT"tiers virus). They also devel­
oped a way to grow the virus in the laboratory, and both 
the American and French laboratories developed tests 
that blood banks could use to search for the presence of 
the virus in donated blood. 
1985: Two simple, grim statistics: By year's end, eighty-three 
percent of the first 500 AIDS patients in San Francisco had 
died. Median survival after diagnosis was eleven months. 
In April, widespread screening of donated blood began 
in the United States to exclude units contaminated with 
the AIDS virus. 
1986: Now the virus that causes AIDS had its own monogram: 
HIV (for human immunodeficiency virus). In clinical 
trials, the antiviral drug AZT was shown to slow, but not 
arrest, the immune destruction in AIDS. A study of AIDS 
in Florida found no evidence to support the fear that 
AIDS might be spread by mosquitoes. 
1987: Concern was rising that the risk of AIDS transmission 
among American heterosexuals might ultimately be as 
high as that being documented in Africa. The concern 
might be overemphasized, but it was not trivial: AIDS 
was now the leading cause of death among intravenous 
drug abusers and hemophiliacs, both groups that include 
many heterosexuals. Thirty percent of America's 1.1 mil­
lion intravenous drug abusers are female, and half of 
these women have a history of prostitution. 
22 
Meanwhile, human testing of two potential AIDS vac­
cines and widespread use of AZT were approved for 
AIDS patients. 








With this issue, there arose in the first minutes of the Seven 
Springs conference the most frus,trating aspect of AIDS re­
search: the lack of an ideal animal model. Although a virus 
that infects some monkeys has many similarities to HIV, and 
although mice have been genetically engineered to have HIV 
in every cell of their bodies, direct infection with HIV itself 
does not cause a disease like AIDS in any species other than 
human beings. 
A scientist studying the common cold can ask volunteers to 
submit to applications of a virus in the interests of science; the 
consequences are uncomfortable but mundane. Obviously, 
such experiments are out of the question for an AIDS re­
searcher. What then? 
Recently, a virus very similar to HIV has been shown to 
cause a disease very similar to AIDS in rhesus monkeys, and 
this is extremely promising as an animal model for AIDS. But 
to date, most researchers have had to resort to less than 
optimal methods in addressing basic questions about the 
AIDS virus. Even with the rhesus monkey model, some ques­
tions-such as the precise mode of entry of HIV into the 
body-may be unanswerable. 
Most of what scientists know about the AIDS virus, beyond 
watching the progress of the illness itself, has been gained 
from studying human cells persuaded to grow in laboratory 
dishes. How much of the ''knowledge'' gained in this artificial 
manner is irrelevant? (As one conference participant put it: "A 
human being is not a tissue culture!") Without a good animal 
model, many theories about HIV will remain nothing more 
than best guesses. 
"We have to be honest with each other," interjected another 
participant early during the first session. "Instead of kidding 
ourselves, somebody ought to take down the message that the 
one thing we do know is that we don't know.'' 
"We do know things about the pathway," countered the 
session chairman, Bernard Fields of Harvard Medical School. 
''We know some of the genes. We often don't know why the 
virus goes in a certain pathway. There are enormous gaps in 
the complexity of the biology. In so many places, we can't 
[obtain] rigorous biochemical proof of a mechanism. But we 
do not know nothing!" 
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1988: Eight years after AIDS was first recognized, it is still 
SYIJonymous with death. 
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' By the time of the Seven Springs Conference in May, 
HIV had spre�d to 111ore Jhan 62,00OAmericans, includ­
ing 39,000 homosexuals, 11,000 drug abusers (and 5,000 
people who fall into both categories), as well as 600 he­
mophiliacs and 1,000 children. Public healtfi experts pre­
dict that by the end of 1993 some 450,000 Americans will 
haveAIBS. 
How bad an epidemic is AIBS? For comparison, every 
year in the United States, approximately: 
1,000,000 people.are diagnosed with cancer 
900,000 people have their first,heart attack. 
150,000 people develop Z-ung cancer 
50,000 people die in highway'accidehts 
. Worldwide, .more than 81,000 .AIDS cases have been 
reported in 133 countries. An AIBS expert at the World 
Health Organiz.ation says the real incidence is probably 
twice as high. By 1990, it is estimated, more than a million 
people will suffer from the disease. 
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MEANS OF ENTRY 
H
owever it gains access to the body, HIV has to enter a
human cell so that it can reproduce. It must invade the 
cell's genetic machinery and use it for its own replication. 
Which cell does it choose? 
Evidently, HIV most often gains access to certain of the 
white blood cells: the helper T cells, the monocytes, and 
macrophages. All of these have important functions in the 
immune system (see p. 30). New studies suggest that macro­
phages may be HIV's first victims inside the body, the refuge 
where HIV hides out and multiplies even before provoking an 
immune reaction. 
At the outset, when AIDS first appeared, researchers fo­
cused on HIV's tendency to infect and kill a certain sub­
population of the T cells of the immune system. Alan Williams 
and Don Mason of Oxford University had recently identified 
a unique molecule called CD4 on the surface of helper T cells, 
and they used it as a label to distinguish these from other 
kinds of T cells. As Mikulas Popovic of the National Cancer 
Institute (NCI) reminded the conference, very early AIDS 
experiments showed that antibodies which bind to CD4 could 
prevent the virus from infecting T cells in the laboratory. When 
this emerged, it seemed obvious to assume CD4 was the lock 
that HIV could open to enter a T cell. 
The revelation that macrophages could also be infected 
came later, and brought with it serious implications. Cells of 
the macrophage type, and their blood-borne relatives the 
monocytes, are everywhere. Macrophages take up long-term 
residence in the lining of organs such as the lungs, the kid­
neys, and the brain. In all these places, apparently, they are 
both housekeepers and nurturers; they produce messenger 
chemicals and also take up and degrade cellular debris. If the 
virus could infect a macrophage-type cell, it seemed there was 
almost no limit to where it might lodge. 
Although cells of the macrophage variety do have some 
CD4 molecules on their surfaces, there's a mtich simpler 
(though as yet unproven) way for HIV to enter: endocytosis, 
the natural process by which macrophages engulf and destroy 
foreign matter and damaged cells. Does HIV usually infect 
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AT RISK 
Male hoµmsexuals: Infectea with HIV via anal intercourse: 
Intravenous dry.g abusers: Infected by sharing syrirlge needles 
with someone carrying HJY in.his or herb!oodstream. 
Hemophiliacs: Infected from contaminated injections of Fg.cto:r' 
VIII; taken to avoid uncontrolled bleeding. 
Transfusion recipients: Infected by receiving clonorblood con­
taminated with MIV. Less tha:ry . two u:ryits, of (dop�ted 
blood in a tl).ousand art� .fou:ryd to be ,infected by H� �nd 
these. units are ·discardeq . • Becat.1se so.me···· researchers. thinl< that the virus; can briefl;y IJ.ide out.in cells withp11t ' 
provokin'.g antibocli�� 1. it has been th�J)��ed .. thafsoll'.le 46Q 
peoJ?le each year might r�ceiy� · •ihfect�q bl9od that· es-
capes detection. . ... . . { . . .. . . ' ( ; Infants of infected moth�rs: rn�eAfIDS x�s reaches them in1/4 
ut�ro, during birth, 0� perhg.ps .. ,.while'nur?ing� ' 
Sexual contac!s o� AIDS. carri�rs:,rye �s apparently caR.be 
transmitted during yord�arr hete1:�sext1�l· .. in�erc�urse .
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. The ac�al risl< · of· cat�hic1� . .,'��S ,�etero�exuglly, �si:,e-- .. 
c i a l l y  f rom a·•··WOfficlJ.1,.. i� iUnknowtrand trigh ! y· 
controvers�al. . . .;. • ( ·, . , . . . . ... ., .. There i8 no evidenc.� to ·support airy s;t1ggestion Jhat . AfIDS can be . spreacl by,.< cg.sual: c011tactr kissi11g, < or in--
sect bites. 
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macrophages via the CD4 receptor, or is it swallowed in the 
normal course of events? 
That leads to another important unknown. If HIV often 
infects macrophages by endocytosis, how can it be stopped? 
Should a macrophage be prevented from doing its regular job? 
"We can't yet answer what it is about the macrophage that 
makes it win or lose against ar�y virus," observed Dr. Fields. 
"This is a critical question that is a gap in our information." 
The latest type of white blood cell to be implicated as a host 
for HIV is the dendritic cell. A principal function of these cells 
is to act as accessory to the normal function of CD4-positive 
cells. If infected, dendritic cells may interfere with T-cell func­
tion, or transmit the virus. 
Another troubling puzzle is where, inside the vagina or 
rectum, the AIDS virus first lodges after being transmitted 
during sexual intercourse. Can an intact vaginal lining be 
infected? 
The cells on the epithelium, the surface lining, of the vagina 
and rectum don't possess the CD4 molecule, the lock that HIV 
can open. Does HIV infect these cells through another open­
ing (in which case many drugs and vaccines proposed to halt 
the infection are useless)? Or must there be some minor injury 
during intercourse, which gives the virus access to underlying 
cells that do bear CD4 on their surfaces? 
The evidence ·is mixed. As Jay Levy of the University of 
California, San Francisco, pointed out, studies from Africa 
show that the risk of heterosexual infection appears to be 
increased in the presence of genital ulcers or of two venereal 
diseases, chancroid and chlamydia. All· of these factors could 
bring immune cells to the surface, where the virus could reach 
them. 
On the other hand, both Dr. Levy and Michael Oldstone of 
the Scripps Clinic and Research Foundation displayed pic­
tures showing evidence of HIV infection in certain cells lining 
the intestine and rectum. But are these really macrophage 
cells that have taken up residence in the gut, where macro­
phages are very common? Photographs alone won't resolve 
the issue; further study is needed. 
"Some of these questions you'll never be able to answer in 
humans," commented Martin Hirsch of Massachusetts Gen-
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WANTED: ANIMAL MODEL 
Acquired immune deficiency syndrome is 
unique to human beings. This simple fact, 
more than anything else about AIDS, has 
slowed efforts to combat the disease. 
CHIMPANZEES can be infected with H[V, 
but they do not proceed to develop immune 
deficiency. 
RHESUS MACAQUE MONKE YS can be 
infected with the simian immunodefi­
ciency virus, SIV, which is closely related 
to HIV in its genetic constitution and its 
effects. Monkeys infected with SIV may re­
main persistently infected or may die of 
problems that parallel AIDS. The rhesus 
macaque is probably the best animal model 
for AIDS available today, and is in great 
demand. However, it is too soon to say how 
much of what may be learned about SIV 
will translate directly to AIDS. 
GENETICALLY ENGINEERED MICE, cre­
ated at the National Institutes of Health, 
contain copies of the AIDS virus in every 
cell. They are the only mammals other 
than humans that get sick from the effects 
of HIV. 
CONGENITALLY IMMUNODEFICIENT 
MICE have been implanted with fetal 
human thymus, liver, spleen, and lymph 
nodes in experiments by Dr. Irving Weiss­
man and Dr. Michael McCune at the Stan­
ford University School of Medicine. As Dr. 
McCune reported these experiments dur­
ing the Seven Springs meeting, only four of 
these mice had been inoculated with HIV, 
and it was too soon to say whether they 
might go on to be infected with HIV or 
develop a disease like AIDS. 







eral Hospital. "You can't study the individual [infectious] 
episode.'' 
"That question, we can't answer in man," agreed Hilary 
Koprowski of the Wistar Institute. "We can reconstruct skin 
in tissue culture. We can do a lot of experiments and show, 
I'm sure, that the virus will get in. But that doesn't mean it 
occurs in vivo." 
It might be possible, however, to learn why some individu­
als remain infection-free despite years of regular sexual con­
tact with a HIV-infected partner. There could be elements of 
the fluid environment in the human vagina or rectum that 
inactivate the virus. These may vary from person to person. 
"This area has not been looked at very much," said Dr. Fields. 




he fate of a cell infected by HIV depends on its cell type.
It appears that HIV ultimately kills helper T cells, but it 
often seems to spare a cell such as a macrophage in order to 
use it as a factory, to assemble new versions of itself. Much of 
what is known about HIV comes from studies of T cells; 
speakers at Seven Springs agreed on an urgent need to repeat 
these experiments using macrophages and monocytes. 
Inside such a cell, HIV probably behaves much like the other 
retroviruses that have been studied in animals (see p. 28). It
allows the cell's enzyme_s to unzip its coat, and proceeds to 
use its own enzymes to translate some of its RNA genetic 
message into DNA. Then the DNA version of the virus's 
blueprint somehow elbows its way into the cell's own genetic 
material, where it may sit silently for years. 
What rouses it into action later, ironically, is probably the 
cell's response (in its normal role within the immune system) 
to the presence of a further infection. In laboratory dishes, 
HIV can be provoked to replicate when '' quiet'' infected cells 
are triggered into action by some immune stimulus. For an 
AIDS patient, the first sign of the disease is often the appear­
ance of a major infection of another kind. 
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THE IMMUNE NETWORK 
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Killer lymphocyte 
When a healthy person gets an infection, he 
or she can mount an astonishing number of 
different kinds of responses to the insult. 
Here are examples of the reactions that can 
be set off by a microbial invader such as the 
measles virus: 
Like internal sanitation engineers, the 
macrophages wipe up the dead infected 
cells, destroying and breaking up the vi­
ruses inside. In the process, the macro­
phages present viral proteins on their cell 
surfaces in a form that T cells can recog­
nize. Dendritic cells also can take up anti­
gens in tissues where they are deposited. 
Their job is to tell the T4 cell that antigen is 
present, and to induce the T4 cell to grow 
and make lymphokines. 
Antibody-producing 
B lymphocyte 
Activated helper T cells secrete soluble 
factors, known as lymphokines, which halt 
the replication of virus and spur the matur­
ation of other lymphocytes into killer and 
more helper T cells. Cytotoxic T cells kill 
virus-infected cells. Helper T cells boost 
the action of phagocytes, as well as of the B 
cells that create antibodies, soluble Y­
shaped structures that recognize foreign 
proteins such as parts of a virus's coat. 
Gradually, after several weeks, a popula­
tion of memory T cells arises, which pre­
serves the ability to recognize the defeated 
virus, should its relatives ever return. 
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Once the cell is activated, the viral DNA inside it begins to 
copy itself and to assemble new AIDS viruses. These collect 
inside the surface of the infected cell and eventually ''bud" 
out, wrapping themselves in part of the cells glycoprotein 
surface before they pull away. 
In laboratory dishes, escaping viruses may pepper the sur­
face of an infected T cell with holes; it appears to explode. This 
makes a dramatic photograph, but is it clinically important? 
Just as easily, the virus can spread directly when an infected 
cell fuses with an uninfected one-or, in fact, with a large 
number of other cells-to form '' giant cells' ' or syncytia. Such 
cell fusion is a neat explanation for some of the clinical phe­
nomena seen in AIDS patients. Whether cell death or cell 
fusion is more important to the immune devastation of AIDS 
is still unclear. 
What is clear is the resulting devastation to the immune 
system. Its routine business requires some cells to touch and 
aggregate, and others to travel long distances through the 
blood or lymph canals, often homing in on the organs where 
immune cells are created or wait at rest-the lymph nodes, 
the spleen and thymus, and the bone marrow. Any one of 
these cells, infected with HIV, could transmit new viruses to 
many other cells. 
It's the worst nightmare of an intelligence chief: One agent 
turns, and before long the entire system is corrupted. Nobody 
knows until it's too late. 
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f AfDS presents daunting problems tbscience, its challenge
to society is equally · complex-and the reaction has often 
been distressing. 
The blind eye: In the United States, the most frequent 
victims of AIDS are members of outcast groups: homosexuals 
and drug addicts, and increasingly a third group, prisoners. 
Compared to the polio, epidemic of the 1950s, which spread 
across a diverse segment of American culture, it was, at least 
initially, far more difficult to raise official and public interest. 
(not to mention funds) to combat the AfDS crisis. 
The cold shoulder: Unlike polio in the 1950s, AfDS appears 
to be unequivocally fatal (until such time as a cure is found). 
Many of the unaffected react with fear and hostility. Children 
with AfDS have been stigmatized by adults; in one case> a 
young AfDS victims house was burned down. Many health 
professionals-doctors, nurses, dentists, even morticians-,­
avoid contact with AfDS victims. Surveys show that many 
who do not shun them fear for their own lives. 
The pointing finger: Society grapples with the competing 
problems of discrimination and the need'tp know. To mon!tor 
and characterize the epidemic, it is urgent to identify which 
people have been infected. AfDS testing is already routine in 
the US military. Many public figures support mandatory AIDS 
tests for various other groups such as immigrants, prisoners, 
and marriage applicants. People infected with HIV face two 
fights: the fight agaiJ.J.st the virus, •attd the fight against 
discrimination. 
The underclass: In America, AfDS is most common in the 
lower socioeconomic classes, and tends to draw health care 
resources ( already scarce) away from poor people who have 
other problems. As a result of AIDS, public hospitals suffer 
shortages of antibiotics;.beds, nurses. Whole wards are t*en 
over by infants with AIDS born to drug-abusing mothers; not 
enough foster homes can �e found. 
The Third World: In part_s of Africa and South America, 
AfDS cripples an already weak health-care system. That 
weakness contributes to the spread of AIDS in tum, because 
blood testing is less common than in the United State� ·�11d 
Europe, and hypodermic needles are used more than once. 
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ow this could happen-how HIV can, in time, com-
pletely eradicate the immune system-is a baffling issue 
that arose again and again at Seven Springs. "The kinetics 
[ rates of progress] of the immune destruction is really a black 
box," said Samuel Broder of the NCI. "Many things about the 
clinical course are very complicated and difficult to under­
stand, including the initial infection which does not lead to a 
sudden, fulminant T-cell depletion.'' 
The latent periods-extended episodes of general health 
despite HIV infection-are characteristic of the disease. The 
virus may seem to be hiding out, because no one is aware of 
it, but is it really inactive? 
In the laboratory, resting T cells or monocyte/macrophages 
appear relatively resistant to infection. And once infected, 
monocytes will not release new viruses without being acti­
vated by an immune-system stimulator, noted Anthony Fauci 
of NIAID. But are these latent cells an arti fact of the 
laboratory? 
Dr. Martin raised the question of what is a truly resting cell. 
The virus itself carries substances that may activate an im­
mune cell to respond as if it had detected a new infection. If 
such a cell is already heavily infected with HIV, the presence 
of these substances in themselves may provoke the manufac­
ture and release of new viruses from the cell. 
"My own feeling is that we need to differentiate a single cell 
or a population of cells from the whole individual," remarked 
Robert Gallo of the NCI. "In the whole human, there is no 
time when you do not, find expression [production of new 
viruses] in some cell. It may be very small at times, but in a 
pool of 100,000 cells, you almost always find some expressing 
the virus.'' 
On average, noted Dr. Fauci, at most one of every 1,000 
white blood cells in an AIDS patient appears to be infected by 
HIV, according to the most sensitive test. Only one of every 
10,000 or even 100,000 is actively producing new viruses. Yet 
even early in the disease, while a patient appears to_be well, 
the population of T cells steadily declines. It's very puzzling. 
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Only; cme feature seemsmvanant: fatality .. :' 
The incubation period of�II)p_:_the ipter�albehveen infec� 
tion .with tfie •· virus and orisetbf serious· tlisease""7is about 
eight years among.adul�s: Someo11e·infected by thf�s may. 
notice a flulike epis.ode and a pe,rioa of weakne�s and lethargy 
shortly after infection; butwill/'ecoyer to remain ·"healtfiy" for. 
some years .. 
A.fter a brief period, peoJ?le iD:fected with IBV dndevefop 
an immune· response to the virus/indwiing.the proquctio11 of 
antibody molecules that' recognize. many constituents . of the 
virus ·including. its\prQtein.coat .. Theseantib dies .. allow·the 
presence of the.virus tobe documentec(,butthey do not stop· 1
the disease. 
During the relatively longfafel}f JJeriod, a· JJart of the JJa­
tiel}ts immune,System begins to aeJJlet� raJJidly. Irt JJarticular, 
__ certain immune cells· KnOWl). as''t4 helJJer cells,· in1pm:fant il} 
·marshafiing the immlllle system.to.,f.ighfinfecfions; decline
JJreciJJitously. The mechanism unoerl)1ng the Joss of. Li cells 
is still· not clear: 
A.t the same timer JJI"Obably so .·
· . .. . er the infection, 
. many
. JJatients begin to experience· psycho!9gka�problems �.uch as 
.aJJathy, lacl< 9f coordination,.and cHffiqulty'°in·comJJletihg or­
dinary .taSKS. These JJFOblems may be subtle/or·may}Jrogress 
to fraliK dementia with alarm.ing.sJJeed.·For eighty.percent of 
JJatiehts witn signs of brain ·:infection, ·full�blown dementia 
develops within a year.. . . .· . . . . . . . . .
. 
Sooner . or fater . the im.mune .·· deJJleti9n ... a.l�o ,. has conse­
quences. ,Many patients deyelopKaJJOSis sarcoma, a· disfigyr­
ing and disseminated cancer.primari ly of · the sl<in. 
Interestingly, · recent s�die� suggest .. ·tha.t.the. incidence of 
.Kaposis is declining among Afnericanswith AfDS. 
A. ffiore sigrrificant 8SJJeCf?fthe fi11al ·d�cline in.�IDS is the.
relentless JJrogression of' 'opJJortunistic't,infections /atta�ks.of · 
illness due to fungi oFl:,acteria that a healtfiy immune system 
couldcontrol ·withotit trouble.�. (The . �9st JJ.ronririent.is �ne11: 
mocy·stis carinii gneumoni�, a lu11g .inteFtton �ormerly.most 
cqmmon among ca,ncer JJc:ltients ana transplal}t reciJJients who 
·are weakened by immundSURJJFessive medications) The o:r-
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"Those of us who follow AIDS patients for years see them 
completely run out of T cells," he said. "We still haven' t 
explained how you ultimately, completely, run out of T cells. 
I' ve been in many discussions, and this has never been 
resolved.' ' 
Nothing in medical history appears relevant to the question. 
The scientists at the conference searched for a good analogy 
that might provide some explanation: Organ transplant pa­
tients treated with immunosuppressive drugs? People with 
the autoimmune disease myasthenia gravis, who have had 
the thymus (the organ where T cells arise) removed as a 
treatment? Bone marrow donors? None of these people com­
pletely run out of helper T cells, as an AIDS victim inevitably 
does. 
There are a number of possible explanations. Recent studies 
show that HIV becomes more virulent (more infectious and 
more deadly to cells) as the disease progresses. It is also 
possible that the immune system contributes to its own de­
struction, by killing infected cells. 
The fusion of infected cells with uninfected ones is another 
attractive explanation. Both in lab dishes and in monkeys, 
giant cell agglomerations called syncytia arise in the presence 
of HIV. In the laboratory, these syncytia die about a day after 
they form. 
However, the syncytia that appear under laboratory condi­
tions are arising in clones of T cells that have grown up from a 
single ancestor blood cell and may be only distant descendants 
of the cell that once traveled in a human's bloodstream. Who 
can know how they may have been altered in the process of 
adapting to laboratory conditions? Depending on the condi­
tions in cell culture, noted William Haseltine of Harvard Med­
ical School, scientists can "push" HIV-infected cells to either 
form syncytia or swell and burst. 
"There's a very complicated, dynamic situation going on," 
he said. ''There are a whole series of factors to consider, which 
will determine if you see syncytia, cell death, or continuously 
virus-producing cells." 
Medical researchers rarely see large numbers of syncytia in 
the lymph nodes or spleens of patients. Even if syncytia do 
form at some stage of the disease, it is not obvious when or 
where to look for them. Are they really important in the 
disease? 
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he explanation for the depletion of T 4 cells may not lie in
the T4 cells at all, but elsewhere in the network-in the 
cells that nourish them as they develop and interact with them 
later in their lives. A virus that infects a macrophage may thus 
be far more deadly than one that kills a T cell. 
Ralph Steinman of The Rockefeller University pointed out 
that traveling immune cells, called dendritic cells, only re­
cently recognized to be infectable with HIV, may carry HIV 
back to regions in the spleen and lymph glands where T 
lymphocytes are often first stimulated during an immune 
response. HIV-infected dendritic cells conceivably could mal­
function, thus reducing the efficacy of the helper T cell re­
sponse; or the infected dendritic cells might transmit HIV to 
the T cells with which they must interact physically to induce 
immunity. 
Cells lining blood vessels in many organs, added Siamon 
Gordon of Oxford University's Sir William Dunn School of 
Pathology, are members of the macrophage lineage. They may 
also be infected and then serve as widely distributed reser­
voirs of HIV. 
In the bone marrow, he went on, a form of mature macro­
phage with many fingerlike projections sits at the center of 
developing monocytes, apparently nourishing them. They're 
CD4-positive, presumably they're infectable, and they sit 
close to other cells which can be infected, Dr. Gordon said, 
making them "an incredible opportunity for the secondary 
spread of the virus." 
He presented a very persuasive scenario for the means by 
which an AIDS virus might rapidly spread its descendants 
across an entire network of immune cells, and it is tempting 
to take it for granted that this is how the infection works. But 
the mechanism is still only a theory. Since the first report in 
1986 showing that HIV could infect monocytes inside an AIDS 
patient, there has been very little further direct evidence­
clinical evidence-that cells of this class are infected outside 
the brain. 
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Two views of how scien­
tists identify cells that are 
producing the HIV virus. 
The top photo illustrates a 
method called immunocy­
tochemistry. An antibody 
(immuno) to a component 
of the HIV virus is iso­
lated from infected pa­
tients, or it is made in mice 
using the monoclonaf anti­
body approach. The ·anti­
body is then added to a 
preparation of cells (cyto) 
here shown by the shady 
oval profiles, each of 
which is one cell nucleus. 
The antibody is coupled to 
an enzyme which then 
chemically produces a col­
ored product. Two anti­
body labeled cells, in 
other words, cells carrying 
HIV protein, are arrowed. 
The bottom photograph 
illustrates a method called 
in situ hybridization. In 
this, molecuiar biology is 
used to make a comple­
mentary copy of the HIV 
messenger RNA, which 
must be made to translate 
the virus's genetic infor­
mation into HIV proteins 
(see p. 42). The copy is 
modified with radioactive 
atoms so that it can be 
used to detect HIV mes­
senger RNA in any test 
sample. When the radioac­
tive probe finds the mes­
sage of the virus in the 
cell, many black spots are 
produced over the cell. 
Photographs supplied 
by Drs. Harm Bos and 
Erik Langhoff of The 
Rockefeller University. 




arly in the infection, the AIDS virus infiltrates the brain.
Even before the immune deficiency arises, said Dr. Broder, 
many AIDS patients begin to show neurological abnormali­
ties, both in brain scans and in psychological tests. 
No one knows exactly how HIV reaches the brain. Infected 
T cells or monocytes could carry it there. Inside the brain, HIV 
infects macrophage-class cells known as microglia, which nor­
mally may perform a nursing function-perhaps nourishing 
brain cells or clearing away spent chemical signals. Whether 
or not HIV infects other kinds of brain cells is a matter of 
debate. 
The brain damage that results can sometimes be reversible: 
AIDS dementia can recede among patients taking the antiviral 
drug AZT. And the physical damage is minor, he added. 
Pathologists often remark at autopsy that the visible damage 
is inappropriately slight in the brains of patients who were 
severely demented before death. 
The mysteries are amenable to study. The products of mac­
rophages of the nervous system, and their effects on the brain, 
I/constitute a key area for research," said Dr. Fields. 
Another fertile area for study is the difference between the 
people infected with HIV who feel healthy and those who are 
beginning to succumb. Fqr example, Dr. Hirsch reported his 
studies of asymptomatic AIDS patients from Greece and the 
United States. When they felt healthy, their white blood cells 
were able to kill about half of their own HIV-infected cells in a 
laboratory dish. But when they developed Pneumocystis 
pneumonia, these responses ( as well as other immune func­
tions) dropped dramatically._ When they took AZT, the labo­
ratory activity of their white cells revived. 
Myron Essex of the Harvard School of Public Health also 
described his studies of people who are infected with HIV but 
appear well. Those who did not progress to develop AIDS ( or 
the related syndrome ARC) during the two years of this study 
had an intriguing property in common: They produced anti­
bodies against a particular small region of the HIV coat pro­
tein. Would this explain how people remain healthy during 
infection? Could it perhaps form a basis for treatment? 




Social ·measures: ,By ,1985, all blood· §citnples in the United 
States. were being tested for evidence of HN infection. This 
has led to a great decrease in the risk of transfusion. "Safe 
sex" -the use of condoms and selectivity in choosing sex 
partners-can also reduce the risk:. In·San Francisco, a mas­
sive pul:>lic education proj�ct dramaticallyreduced the proppr­
tion ofw1y· men testing J.'O�itive for HIV;infection during the 
course·of four years. Signs of AIDS infection were detected in 
more than one in five male homosexuals newly tested for the 
antibody in 1982. The prevalence dropped below one fa a 
hundred gay men tested.in 1986. 
Vaccines: The AIDS virus itself cannot be used as a vaccine 
becaµ.SfJt is invariablytfatal. A weaken��!er killed vi�s, �s 
used·in· some influenza.and polio vaccines/may be too risky 
to use for vaccinating healthy people (although Jonas Salk, 
developer of a polio vaccine, is trying it as a way to boost the 
immune response in people who already have AIDS). Two 
artifici�l AIDS vaccines are currently under testing in human 
volunteei:s in the Unite�;States. Both USfc� virus harmless to 
humans, which is ge11etically engineereu to contain a small 
fragment of HIVs protein coat as an immune stimulus. 
In March 1987, a French researcher announced that he had 
injected a small group of volunteers in Zaire, and himself, 
with a "vaccine" consisting of inactivated virus. They all de­
veloped antibodies against the virus, and some also showed 
an incr,ease in 'the activity·of T lymphpcytes. All three pro­
posed vaccines provoke the production of antibodies, but it is 
too soon to say whether these can prevent the disease. 
In England, . testing has begun on another sort of vaccine, 
which incorporates a protein from the viruss core (rather than 
from its outer coat). 
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WHY NOT A VACCINE? 
P
eople do not succumb to the human immunodeficiency
virus simply because their bodies fail to recognize its 
presence. Very early in the infection, AIDS patients do react 
to the virus. They naturally produce antibodies, well-charac­
terized proteins that recognize HIV and should lead to its 
defeat. 
In most cases, these antibodies, which are known as neu­
tralizing antibodies, easily conquer an infection. In fact, many 
vaccines work by intentionally provoking their creation. Vac­
cines provide the immune system with an innocuous first 
introduction to a pathogen (as sometimes do reminders that 
are known as booster shots). If the agent appears later as an 
infection, the immune system can respond quickly. It re­
sponds first with antibodies, which both initiate an antiviral 
response and remember the virus for years. 
But the first antibodies against HIV are not as good as the 
name they are given. They fail to neutralize the virus, either 
in cell culture or, evidently, inside the body. This confounding 
fact provides one main reason why the best strategy against a 
viral disease, a vaccine, proves unexpectedly elusive in the 
case of AIDS. 
In 1984, when HIV was isolated, the head of the United 
States Department of Health and Human Services cheerily 
predicted there would be an AIDS vaccine in two years. Four 
years later, in a quick show-of-hands vote at the Seven Springs 
conference, only about half of those present felt there will be 
an AIDS vaccine in ten years, and no one would bet on five 
years. 
The AIDS virus presents a daunting challenge for vaccine 
developers. Its protein coat is heavily masked by complex 
sugars. It mutates rapidly, giving descendant viruses an op­
portunity to escape an immune response designed against 
the parent virus. Furthermore, the virus tends to hide out 
inside cells where an immune system can't see it under any 
circumstances. 
History provides some discouraging precedents, Dr. Ko­
prowski remarked as the discussion of vaccines began at 
Seven Springs. Progress against livestock lentiviruses-which 




Nearly 80 years ago, an unusual visitor 
came to the laboratory of a young cancer 
researcher, Peyton Rous, at The Rockefeller 
Institute for Medical Research (now The 
Rockefeller University). A chicken breeder 
arrived at the lab, accompanied by his hen, 
which had a malignant tumor called a sar­
coma on its leg. 
Rous removed the tumor, filtered off the 
cells, and injected other chickens with the 
remaining liquid. They developed similar 
tumors. Rous decided that an agent too 
small to be seen under the microscopes of 
1911, perhaps a virus, was at fault. His idea 
was greeted with resounding silence at the 
time. But he was right. 
Some viruses that cause human disease, 
such as the agents that cause chicken pox or 
hepatitis, are made of the same genetic ma­
terial that acts as a blueprint for human 
cells: deoxyribonucleic acid, or DNA. 
These viruses act by inculcating themselves 
directly into the cells they infect. Many tu­
mor viruses, such as the Rous sarcoma vi­
rus, are made of an alternative kind of 
genetic material: ribonucleic acid, or RNA. 
When human (or chicken) cells divide, 
they copy their DNA into more DNA. Ge­
netic information in the DNA is tran­
scribed into messenger RNA, which then is 
translated into protein. The protein carries 
out the functiQn of the gene. In animals, 
the flow of information is DNA to RNA 
(and then to protein) and not the other way 
around. So how could an RNA virus ever 
proliferate in an animal cell? 
The puzzle was solved only in 1970, 
when David Baltimore of MIT and Howard 
Temin of the University. of Wisconsin dis­
covered an enzyme, reverse transcriptase, 
peculiar to RNA viruses. These viruses 
use it to translate their genetic code "back­
wards" into DNA. Thus their name: 
retroviruses. 
Retroviruses became a mainstay of bio­
technology because they allow scientists to 
isolate genes, by starting from readily ac­
cessible messenger RNA in cells, and also 
to insert new genes into cells. Many retro-
Internal Viral Protein 
Reproductive Enzymes 
Reverse Transcriptase 
Proteins of Envelope 
RNA Genetic Material 
viruses, in addition to the chicken Rous 
sarcoma virus, were found in animals. But 
to medical science they were nothing more 
than interesting curiosities until 1980, 
when Robert Gallo and his coworkers at the 
NIH reported that a retrovirus could cause 
a rare leukemia in humans. Then, in 1983, 
the retrovirus that causes AIDS came to 
light. 
The genetic material of the HIV virus, 
diagrammed here with wavy lines, encodes 
reproductive enzymes, internal virus pro­
teins, and other envelope proteins. Their 
assembly into new virus particles is dia­
grammed on page 44. Additional HIV 
genes that play a regulatory role in virus 
production are diagrammed on page 46. 
Every vertebrate species studied for re­
troviruses has been found to be susceptible 
to at least one. Some retroviruses are ap­
parently harmless, a number of them cause 
cancer, and others cause a wide range of 
noncancerous degenerative diseases such 
as AIDS. 
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are in the same class of pathogens as HIV-has been negligi­
ble, despite a great deal of money and effort, because of the 
same properties that are outsmarting the AIDS researchers. 
The visna virus of sheep, a very close relative of HIY, 
mutates so rapidly that (as a population) it slips away from a 
vaccine undaunted. Another sheep lentivirus that causes a 
neurodegenerative disease known as caprine arthritis enceph­
alitis provokes so-called neutralizing antibodies that do not 
neutralize inside the animal at all. 
On the other hand, Dr. Koprowski noted, veterinary vac­
cines against rabies and herpes can protect animals without 
provoking a trace of neutralizing antibodies. Presumably the 
vaccine elicits other forms of protection such as T-cell­
mediated immunity. Its easy to test such vaccines in animals, 
by taking the chance they will work. Testing a vaccine against 
a uniformly fatal disease using human volunteers is another 
matter entirely. 
Nonetheless, some human volunteers are already part of 
studies directed at developing an AIDS vaccine. In Zaire, 
Daniel Zagury of the Pierre and Marie Curie University of 
Paris has injected himself and a small group of healthy volun­
teers with a prototype vaccine made by genetic engineering. It 
incorporates a portion of the HIV coat (a protein called gp160) 
into vaccinia, the virus used to vaccinate against smallpox. 
Afterwards, Dr. Zagury and his volunteers developed an 
antibody response against HIV, and in laboratory tests, the 
white blood cells of some of those who had received the 
vaccine were able to kill cells infected with the virus. These 
responses have lasted for longer than a year. But would they 
protect any of the volunteers against a real HIV infection? The 
only way to arrive at an answer would be by infecting vacci­
nated individuals with live virus in order to determine if the 
vaccine is protective. 
In the United States, the Federal government and six medi­
cal centers are recruiting volunteers for different studies using 
direct injection of viral coat proteins, either gp160 or its sub­
unit gp120, as a vaccine. The question is whether these vac­
cines will provoke any better response than the neutralizing 
antibodies that fail to protect AIDS patients in the first place. 
These misnamed neutralizing antibodies bind to part of the 
viral protein tailed gp 120, which is apparently the protein 
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OPERATING PLAN 
FOR A RETROVIRUS 
Like all viruses, retroviruses consist of a 
genetic core, which contains two single 
strands of genetic material wrapped in pro­
tein, and an outer coat or envelope, a mem­
brane studded with glycoproteins. An 
infecting retrovirus also carries along its 
own enzymes. (See p. 42.) 
Having infected a cell, a retrovirus uses 
its own enzymes to reverse transcribe its 






it into the cell's genetic sequence. At some 
later point, it uses the host's machinery, 
under the direction of viral signals, to du­
plicate its genetic code and to transcribe 
this code into messenger RNA and protein 
so that it can assemble new copies of itself. 
Somehow, the genetic material and core 
proteins of the new viruses congregate near 
the cell's envelope and bud outwards to 
form new viruses. 
Budding of Release of 
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''key' ' on the virus coat that initially fits the lock of the CD4 
protein on an immune cell before th� virus opens it and enters. 
Parts of this gp120 protein represent one of the few sites on 
the virus coat that are conserved; that is, remain unchanged 
by mutation. 
Evidently, conserved sites are preserved by nature because 
they are integral to the function of the virus. In order to create 
a workable vaccine, its desirable to use such conserved regions 
of a viral coat as a target so that the virus cannot escape the 
vaccine by mutating. 
It's likely, speakers at Seven Springs predicted, that vaccines 
against this conserved region of gp 120 will not be completely 
successful in themselves. First of all, there are theoretical 
reasons why they may have untoward effects. In a sense, the 
neutralizing antibodies that bind to the conserved fragment of 
gp 120 may partly resemble CD4 itself, much as any lock a key 
will open must resemble any other lock it will also open. Will 
large numbers of antibodies raised against a viral protein that 
binds to a T cell interfere with molecules that should do so 
normally? 
It would take a large number of antibodies to do the job. 
Using CD4 as the basis for an antiviral strategy, raising anti­
bodies against the viruss recognition site, or "key," requires 
the molecular equivalent of outnumbering the enemy more 
than ten to one. It may be impractical to achieve this inside the 
human body. Finally, there is no proof that these antibodies 
could prevent transmission of HIV from one infected cell to 
another. 
Recent research points to another site on the virus coat that 
is more variable, but which may also be vital to the virus's life 
cycle. Dani Bolognesi of Duke University told the Seven 
Springs conference about his work with this site, called the N 
site, which was discovered by injecting animals with gp160 or 
its subunit gp120. They produced antibodies different from 
the neutralizing antibodies that have been seen routinely. 
More of these alternative antibodies were later found, in small 
amounts, in some AIDS patients. 
Antibodies that bind to the N site appear not to prevent the 
virus from initially binding to a cell, but they do block its later 
fusion to the cell wall and prevent the formation of syncytia. 
Researchers studying the N site believe it is involved in a 
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Genetic engineering has provided a de­
tailed genetic knowledge of HIVl and 
HIV2. T he functions of most of the virus's 
genes are known, though exactly how they 
work is not. 
HIV contains three genes common to all 
retroviruses: env, pol, and gag. Env en­
codes the instructions for making HIV' s 
outer envelope. Gag encodes the informa­
tion for the inner protein in its cylindrical 
core, and pol contains the code for the vi­
rus's own enzymes involved in such key 
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In addition, HIV' s genome contains a 
number of novel genes (many of them re­
cently renamed). Together, they create a 
sophisticated system to control the virus's 
reproduction. 
Some of the novel genes, such as NEF 
(formerly 3' orf), appear to slow down 
the- production of new virus. Other genes 
seem to enhance the virulence of the AIDS 
virus. VIF (formerly sor) increases its 
ability to infect new cells. TAT and REV 
(formerly called trs/ art) regulate the pro­
duction of new HIV's. Another gene, VPR, 
has unknown functions as yet. 
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structural change whereby the virus anchors firmly to the cell 
wall after docking onto CD4; perhaps it helps to "tum" the 
"key" after it is inserted in the lock. 
Antibodies directed against this site on the virus are no 
more likely than antibodies against the other gp120 site to 
form a useful vaccine in themselves. Dr. Bolognesi has been 
looking for versions of these antibodies in a laboratory worker 
accidentally infected with HIY. He found that, after about a 
year, the HIV isolates inside the patient had begun to mutate 
in ways that could escape the antibodies directed against the 
N site. 
Antibodies are only a small part of the immune response, 
of course. On one arm· of the immune system, white cells that 
arise from the bone marrow manufacture antibodies; on the 
other arm, white cells that come from bone marrow and pass 
through the thymus become T cells which kill viruses. 
T hese two recognition systems don' t even "see" a virus in 
the same way, Jay Berzofsky of the NCI pointed out. T cells 
never see the virus coat floating free in the bloodstream; they 
see pieces of it on the surface of another immune cell that has 
digested and processed the virus. Perhaps, he reasoned, it is 
possible to bypass antibodies entirely and design a vaccine 
that will stimulate T cells. 
Which fragments of the virus tend to emerge on the surface 
of an antigen-presenting cell, where the T cells can find them? 
Dr. Berzofsky addressed the question by asking what 
structural properties are common to the molecule fragments 
known to stimulate a reaction from helper T cells. About three 
out of four such fragments, he has found, are helical, with one 
face of the helix having an affinity for water and the other face 
being hydrophobic, or water-repellant. "This structure," he 
remarked, "would tend to chemically stabilize a protein on 
the surface of the target that the helper cell must recognize." 
Using computer modeling, Dr. Berzofsky has been 
analyzing the AIDS virus coat for chemical sites that match 
this two-sided helical pattern. To be useful for a vaccine, he 
reasoned, such sites should also come from a part of the viral 
coat known not to mutate frequently, and should not be 
heavily masked by complex sugars. He found two molecule 
fragments on HIV's glycoprotein coat that appeared to fit these 
criteria. 
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Scanning electron micro­
scope views of two of the 
other cell types that can be 
infected with HIV: macro­
phages (top) and dendritic 
cells (bottom). Like helper 
lymphocytes, some macro­
phages and dendritic cells 
can express the T4 or CD4 
molecule. Recall that T4 is 
the lock recognized by the 
gp120 protein key on the 
virus, permitting infection 
of the T4-bearing cells. 
The macrophage is a 
phagocyte which actively 
scavenges, engulfs, or eats 
(phagocytoses) organisms. 
In some cases, the macro­
phage is permissive and is 
used as a site for intracell­
ular microbial growth. 
The immune interferon 
that is produced by T4 
helper lymphocytes makes 
macrophages less permis­
sive or more microbicidal. 
The dendritic cell is a 
sentinel cell which takes 
up small amounts of for­
eign materials or antigens. 
The cell then moves ac­
tively to find T cells that 
recognize antigenic frag­
ments on the dendritic cell 
surface. This surface con­
sists of many long sheet­
like or spiny processes 
(veils, dendrites) which 
are used to probe the envi­
ronment for T cells. Once 
an antigen-specific T cell 
is bound, the T cell starts 
to multiply and produce 
lymphokines like immune 
interferon. 
Photographs supplied 
by Ors. Gilla Kaplan and 
Ralph Steinman of The 
Rockefeller University. 
AIDS: Defining the Battle Lines 
,.. 
SCIENCE 
Dr. Berzofsky was able to test a vaccine made from one of 
these fragments on Dr. Zagury and ,some of his volunteers in 
Zaire. In laboratory tests, T cells from Dr. Zagury himself and 
eight of his healthy volunteers produced a strong immune 
response against HIV-infected cells after injections with Dr. 
Berzofskys trial vaccine. But the upshot of the study was 
discouraging: Dr. Berzofsky's ''new' ' site that stimulates Tcells 
turned out to be identical to the viral site recognized by 
neutralizing antibodies. It only underscores, he remarked, 
how few antigenic sites, or epitopes, this virus gives human 
researchers to work with. 
Other viruses than HIV have the habit of changing their 
coats slightly to evade vaccination, but many of them also have 
enough antigenic sites on their surface that multivalent 
vaccines-designed to seek out a number of sites-can 
generally provide protection. Given HIV's generally high 
mutation rate, its own paucity of recognition sites "augurs 
very ill if you play it out," mused Barry Bloom of the Albert 
Einstein College of Medicine. If you immunize a patient 
against one of these few known antigenic sites, he predicted, 
it's reasonable to expect that inside any patient the vims will 
eventually mutate at that site, escape the immune response, 
and you will have gained nothing. 
Even if, by magic, researchers could produce a fail-safe 
vaccine today, remarked Richard Lerner of Scripps, it would 
be difficult to establish whether or not it could work. For a 
sexually transmitted disease, where and how would you 
inoculate? In its venereal form, HIV may spread rampantly 
before it is visible to immune cells or antibodies in the blood. 
At any rate, any sensible person, vaccinated or otherwise, will 
try mightily to avoid catching the AIDS virus. In that 
circumstance, how long will it take, testing how many 
volunteers, to decide that a vaccine is effective? 
"I go to fifteen to twenty-five AIDS meetings a year," Dr. 
Koprowski said. "All of them tum around how to improve the 
vaccine. We should put great pressure on the SIV people 
[researchers studying a monkey vims closely related to HIV] 
to move with great speed to test vaccines." 
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DRUG TREATMENTS 
As yet there is no cur�for AIDS. The�ohly drug approved 
fiby the Food and·Drug Administration for AIDS treat­
ment, 3'Azido2', 3'Dideoxythymidine (AZT or zidovudine), 
slows the progression of the disease and relieves some symp­
toms for as long as it is taken. But it has serious side effects. 
A large number of potential anti-AIDS medicines are in 
clinical testing, both inside pharmaceutical companies and in 
multicenter trials sponsored by the National Institutes of 
Health. About 4,000 patients have been enrolled in the NIH 
trials since January 1988. 
Drugs under testing include: 
AZT: Approved by the. FDA in Marcb)987, after a study 
showed only one death among 145 patients taking the drug for 
seven months, as against nineteen deaths among the 137 
people who took a placebo. It is now sold by Burroughs­
Wellcome under the brand name Retrovir. AZT ultimately 
depletes the white blood cell count, which makes it unsatisfac­
tory as a sole treatment.)t is currently beingtested in combi­
nation with other anti-AIDS drugs, an�f also in individuals 
who are infected with HIV but have not yet developed symp­
toms of AIDS. 
ddC (dideoxycytidine): Similar to AZT in action, but caus­
ing different side effects: neurological symptoms such as 
weakness and defects i11 the sense of touch. ddC improv�s 
immune cell counts and .. body; weight. iri patients who have 
taken it. Being tested in schedules that alternate ddC with 
AZT, to limit side effects, and also in combination with other 
drugs such as interferon. 
Dextran sulfate: A sugarlike compound which seems to 
inhibit the virus from binding to cells. 
Interferon and other cytokines (prodqc!� of healthy T cells): 
Immune-system boosters that may retard tlte progress of the 
AIDS-associated cancer, Kaposis sarcoma. 
Ampligen: Another immune booster, it restores the func­
tion of some immune cells and is thought to control virus 
replication. 
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DRUG APPROACHES 
( "I can' t resist pointing out the irony," remarked Dr. Broder.
''Four years ago, vaccines were considered the way to go, 
and drugs against AIDS were considered inherently 
impossible.' ' 
Today the reverse seems to be the case. About thirty drug 
candidates are being tested on AIDS patients. One of them, 
AZT or 3'Azido2', 3'Dideoxythymidine, has been shown to 
have some effects in retarding the progress of the disease in 
human beings, even though it is not a cure. 
Most of the drugs currently considered for AIDS have been 
pulled down from the shelf and dusted off-the products of 
abortive drug development in pharmaceutical companies, 
which could find no use for them earlier. Better treatments 
may arise from research specifically directed at interrupting 
some part of HIV's life cycle. In the near term, Dr. Broder said, 
the best prospects seem to be drugs that can prevent HIV 
from translating its genetic blueprint into new virus particles, 
since this requires a number of events that are used by the 
virus and not by most normal cellular genes. Another prospect 
would be to prevent HIV from binding to a cell. 
Already, a number of laboratories have succeeded in block­
ing the viruss entry into cells by flooding a laboratory dish 
with artificial versions of the CD4 molecule. Another ap­
proach would be to link a toxin to a version of the CD4 site, 
killing any virus that grabs it. 
"It would be a difficult job for the virus to develop a strategy 
to evade this," Dr. Broder pointed out. Those mutants less 
likely to bind to the drug and be destroyed would also be less 
likely to lock onto immune cells. 
A less specific drug, the polysaccharide dextran sulfate, 
may act by interfering physically with the binding of the virus. 
Long used safely as an anticoagulant, it is now under testing 
against HIV 
About 20 compounds exist that can prevent a virus from 
creating a DNA version of its own genetic blueprint, which it 
must do in order to infiltrate the DNA of the cell it has entered. 
Many of them work more or less like AZT: With a simple 
chemical modification, such as the addition of an oxygen 
atom, biochemists create an abnormal version of a DNA build-
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GM-CSF (granulocyte-macrophage colony stimulating 
factor): An immune sy�tem modifier thal}timulates produc­
tion of white blood cells. Tested in combination with AZT. 
CD4 · agonists: Molecules that mimic the structure of the 
molecule called CD4 on the surface of immune cells, with 
which the AIDS virus links to gain entry. Five different re­
search groups have shown that these molecules can signifi­
cantly block the virus in laboratory ciishes. Preliminary 
studies show that mo�eys tolerate the drug without obvious 
harm. Clinical trials are underway. 
Ribavirin: An antiviral drug shown in some studies to 
prevent the lymph-gland swelling that progresses to AIDS 
and also the development of Pneumocystis carinii pneumonia. 
Unfortunately, recent studies show that ribavirin also inhibits 
the body reactions nece��ary to convert AZT to its active form, 
and therefore can hinder the effectiveness of the only govern­
ment-approved AIDS treatment. 
Many of these drugs, and a wide variety of other treatments, 
are available to AIDS patients on the black market. T his makes 
it very difficult to assess AIDS treatments objectively .. Re­
searche�s cannot be certc!in whether or f\()t a patient rriay be 
concurrently taking another drug that either improves or hind­
ers the effects of the drug ( or placebo) in the official study. 
While many researche,rs are trying to find a way to stop 
AIDS itself, it is up to medical doctors to try to fight the other 
illnesses that inevitably arise after AIDS infection. Because 
the ·imnmne system is �.lready weak, th�y need to find new 
treatments in additionfo the standard antibiotics. For exam.::
ple, Henry Murray of New York Hospital reported at Seven 
Springs that he and a number of other researchers are testing 
the use of immune modifiers such as gamma interferon to 
stimulate AIDS patients' ability to fight opportunistic infec­
tions. It is these infections, not the HIV infection itself, that 
are ultimately fatal. 




ing block that cannot form the chemical bond needed to ex­
tend the DNA molecule. The virus adds AZT to the DNA 
polymer, and the polymer stops growing. 
Because the virus relies on a cell's own enzymes to construct 
its DNA transcript, it is totally vulnerable to such a strategy. 
In vitro, AZT can inhibit the replication of HIV at doses ten to 
twenty fold lower than the doses that impair the survival of 
human cells themselves. 
But such drugs do interfere with cells' own DNA manufac­
ture, and so cause some harm, because they do stop cells from 
dividing or repairing damage to their genetic material. Studies 
are now underway to test alternating AZT and ddC as a way 
to control the virus without disabling side effects such as nerve 
disorders or anemia. 
These drugs are the mainstays for the near future, Dr. 
Broder said. There are a number of other ways in which HIV 
may be vulnerable to defeat by drugs: 
D Reverse transcriptase: This protein translates HIV's RNA 
genetic code into the form that can be inserted into the 
human cells genes. Because it is unique to viruses, a drug 
that inactivated it might do no harm whatever to human 
cells. 
D The TAT gene: In tissue culture, TAT seems to allow HIV to 
gear up its production of new viruses. The protein through 
which TAT has its effects has been identified, and ways may 
be found to block it. TAT is essential for virus production. 
D The REV gene: AIDS viruses use REV to manufacture 
structural proteins, such as the viral coat. Drugs that block 
REV could also block the virus's life cycle. 
D Glycosylation inhibitors: These chemicals can prevent the 
virus from chemically adhering complex sugar molecules to 
its exterior. Because the dense layer of sugar molecules that 
coat an AIDS virus appear to be one way it evades recogni­
tion by the immune system, finding a way to leave the virus 
coat "naked" could be a very effective strategy. 
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SCIENCE 
OF THE FUTURE 
E
ight years on, this is most of �hat we know about the
science of AIDS. If the questions seem to outweigh the 
statements, consider the epidemic that terrified America in 
the other half of this century. 
It was 1916. Public hygiene had begun to defeat diseases 
such as diphtheria and typhoid in American cities and, as they 
would a half-century later, many people began to regard 
medical science as all but invincible. Suddenly, for no evident 
reason, an outbreak of polio swept across New York City, 
striking people without regard to any kind of distinction. 
Despite being a victim of the disease, Franklin Delano 
Roosevelt won the 1932 presidential election and became a 
vital symbol of courage during a long period when almost 
nothing was known about the polio virus. It took nearly 40 
years to develop an effective vaccine. 
By 1981, the year when a few male homosexuals in New 
York died of tenuous rare infections, most Americans took for 
granted that high-tech medicine had made intractable epi­
demics a thing of the past. Nature brought them up short. 
It is now clear that AIDS will have a far greater impact on 
the world than anyone dreamed in 1981. We may have to 
accommodate it in the long term, as we accommodate cancer, 
mental illness, and poverty. But in contrast to the struggle 
against polio, we have started off knowing much more, and 
our tools are far better. 
Because HIV uniquely strikes at our ability to combat infec­
tions, what scientists must learn as they defeat it will unques­
tionably have a major impact on medical science at large. 
Because of AIDS, someday we will understand better how to 
identify and confront other known viral diseases-and, prob­
ably, many more not yet linked to known viruses. AIDS re­
search will certainly improve our understanding of the normal 
immune system, and of other diseases in which it goes wrong. 
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